Eur J Clin Pharmacol:如何降低老年住院患者中潜在不恰当药物的使用?

2017-11-06 吴星 环球医学

2017年7月,发表在《Eur J Clin Pharmacol》的一项由加拿大科学家进行的随机对照试验,考察了老年住院患者中靶向潜在不恰当药物使用的降低。

2017年7月,发表在《Eur J Clin Pharmacol》的一项由加拿大科学家进行的随机对照试验,考察了老年住院患者中靶向潜在不恰当药物使用的降低。

目的:老年住院患者中潜在不恰当药物(PIMs)的使用是一个复杂的问题,但是计算机警报系统(CAS)的使用已显示出一些潜力。本研究的目的是评价与常规临床治疗相比,基于CAS的药师-医师干预模式中PIM使用的变化。

方法:在一所大学教学医院开展一项实用单中心随机对照试验。使用筛选的Beers或STOPP标准,确定住院治疗,并随机分配至临床治疗组或基于CAS的药师-医师干预组。主要结局为PIM药物停用或剂量降低。评价CAS警报的临床相关性。

结果:分析纳入231例患者,对照组和干预组分别有128例和126例住院。患者的平均年龄为81岁,60%为女性。与对照组相比,警报后48 h(45.8 vs 15.9%;绝对差异30.0%;95%CI 13.8~46.1%)和出院时(48.1 vs 27.3%;绝对差异20.8%;95%CI 4.6~37.0%)干预组药物停用或剂量降低更常见。在所有警报的事后分析中,无论临床相关性如何,干预组与对照组之间48 h和出院时药物停用或剂量降低的绝对差异分别为16.2%(95%CI 2.9~29.6%)和8.0%(95%CI -4.0~20.0%)。

结论:在住院老年中,与普通临床治疗相比,基于CAS的药师-医师干预可显着增加靶向PIMs药物停用和剂量降低的数量。

原始出处

Cossette B, éthier JF, Joly-Mischlich T, et al. Reduction in targeted potentially inappropriate medication use in elderly inpatients: a pragmatic randomized controlled trial. Eur J Clin Pharmacol. 2017 Jul 17. doi: 10.1007/s00228-017-2293-4.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1788263, encodeId=3b891e88263e5, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Nov 15 02:11:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787371, encodeId=4f6f1e87371ad, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jun 22 16:11:00 CST 2018, time=2018-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996081, encodeId=e91f199608199, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 04 22:11:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908348, encodeId=ead619083483c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 08 08:11:00 CST 2018, time=2018-01-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1788263, encodeId=3b891e88263e5, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Nov 15 02:11:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787371, encodeId=4f6f1e87371ad, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jun 22 16:11:00 CST 2018, time=2018-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996081, encodeId=e91f199608199, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 04 22:11:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908348, encodeId=ead619083483c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 08 08:11:00 CST 2018, time=2018-01-08, status=1, ipAttribution=)]
    2018-06-22 jj000001
  3. [GetPortalCommentsPageByObjectIdResponse(id=1788263, encodeId=3b891e88263e5, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Nov 15 02:11:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787371, encodeId=4f6f1e87371ad, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jun 22 16:11:00 CST 2018, time=2018-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996081, encodeId=e91f199608199, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 04 22:11:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908348, encodeId=ead619083483c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 08 08:11:00 CST 2018, time=2018-01-08, status=1, ipAttribution=)]
    2018-01-04 yb6560
  4. [GetPortalCommentsPageByObjectIdResponse(id=1788263, encodeId=3b891e88263e5, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Nov 15 02:11:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787371, encodeId=4f6f1e87371ad, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Jun 22 16:11:00 CST 2018, time=2018-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996081, encodeId=e91f199608199, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 04 22:11:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908348, encodeId=ead619083483c, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 08 08:11:00 CST 2018, time=2018-01-08, status=1, ipAttribution=)]

相关资讯

中南药学:1例老年患者多重耐药铜绿假单胞菌肺部感染治疗的病例分析

铜绿假单胞菌(PseudomonaAaeruginosa,PA)又称绿脓杆菌,是临床常见的条件致病菌,其引起下呼吸道感染病死率极高;当人体接受侵袭性操作或免疫力下降时,常会导致感染的增加,临床多见于长期应用激素、机械通气、免疫缺陷以及使用多种广谱抗菌药等情况。近年来随着广谱抗菌药的广泛使用,PA耐药现象日趋严峻,多重耐药和泛耐药菌株给临床治疗带来困难,因而如何合理使用抗PA药物具有重要意义。现就临

重复:J Clin Oncol:来那度胺用于DLBCL老年患者一线维持治疗结果喜人

2017年8月,发表在《J Clin Oncol》的一项由法国、澳大利亚、西班牙等国科学家进行的研究比较了来那度胺维持治疗和安慰剂用于一线利妥昔单抗+环磷酰胺、阿霉素、长春新碱和泼尼松治疗的弥漫性大B细胞淋巴瘤(DLBCL)老年患者的有效性。

2017 ESA指南:老年手术患者围术期静脉血栓栓塞预防

2017年9月,欧洲麻醉学会(ESA)静脉血栓栓塞工作组发布了老年手术患者围术期静脉血栓栓塞预防指南,70岁或以上老年共病患者围术期静脉血栓栓塞风险增加,本文主要针对老年手术患者围术期静脉血栓栓塞的预防提出来7条建议。

黑龙江省医院普外科主任被刺,行凶者竟是一位老年患者!

8月15日上午8时许,黑龙江省医院香坊院区发生一起伤医事件。

J Clin Oncol:急性髓性白血病老年患者的终末期治疗有待改善!

急性髓系白血病(AML)老年人的发病率逐年上升,平均发病年龄为67岁,老年患者易合并脏器功能不全,预后较差。2017年10月,发表在《J Clin Oncol》的一项由美国科学家进行的基于人群、回顾性、队列研究,考察了AML老年患者的终末期医疗保健情况。

围术期疼痛的全程管理病例_老年患者行右半结肠癌根治术围术期镇痛管理病例

患者男性,80岁,体重50 kg,身高175 cm。因“反复腹痛、腹胀、腹泻伴恶心呕吐1月”入院,术前诊断“右半结肠占位性病变并肠梗阻”,拟行“右半结肠癌根治术”,患者自发病以来,食欲欠佳,精神较差,睡眠较差,体重减轻5 kg。